The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
about
The challenge of developmental therapeutics for adrenocortical carcinomaNext-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.Novel targeted therapies in adrenocortical carcinoma.Diagnosis, treatment and outcome of adrenocortical cancer.Cushing's syndrome: an update on current pharmacotherapy and future directions.5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo.Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumorsAvelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
P2860
Q28072970-03B11203-E83C-4662-B549-909778456597Q34431264-6AE9E210-3A29-4B7B-A04B-987B21420F5EQ35170232-E8DC472D-C181-4942-8B4C-3CCBCB592981Q36951577-BAA38FF7-0004-4AE0-9FFC-7DE574437109Q37233378-0A938104-08C5-4375-A9BC-D0DD995638DEQ38358503-47DEDFF2-3A8E-42BA-8500-31B7C5342730Q38541695-6442AFE2-625E-4552-894E-42F74C198450Q38686201-2F81549C-75F5-4F28-A9F2-D1245D984F39Q47321196-0E003FC8-0C8D-40B5-955D-88474FA2FDDFQ49676347-B2AAB772-F1F4-46EF-8A2A-37E754A24B4EQ57291575-318496D6-94D8-4639-9C8C-E9CA2DB79D44Q57803796-7A3F83DC-0D73-4345-876E-8C7AE496990A
P2860
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@en
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@nl
type
label
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@en
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@nl
prefLabel
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@en
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@nl
P2093
P2860
P356
P1476
The VEGF inhibitor axitinib ha ...... apy for adrenocortical cancer.
@en
P2093
Aradhana M Venkatesan
Ciara O'Sullivan
Dat Nguyen
Margarita Velarde
Maureen Edgerly
Sherry X Yang
Stefania Pittaluga
P2860
P304
P356
10.1210/JC.2013-2298
P407
P577
2014-01-01T00:00:00Z